MEDTECH INSIGHT

19 Feb 2021 | News

QUOTED. 19 February 2021. Jeff Shuren.

by

The head of the US FDA's device center tells *Medtech Insight* that COVID-19 is taking a toll on the agency's ability to review premarket applications. See what Jeff Shuren, director for the agency's Center for Devices and Radiological Health, said about it here.

"I know that some people have said ... 'Hasn't this shown that, in fact, we can do more with less? ... And my answer to that is 'hell no.'" – Jeff Shuren, CDRH director, US FDA

• Find out more: FDA's Shuren: Staff Overburdened, Review Times Seeing Negative Effects

Click here for a free trial of Medtech Insight